Bicycle Therapeutics Plc ADR (NASDAQ: BCYC)’s stock price has gone decline by -18.32 in comparison to its previous close of 9.06, however, the company has experienced a -9.87% decrease in its stock price over the last five trading days. businesswire.com reported 2025-05-05 that CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on May 1, 2025, the Compensation Committee of the company’s Board of Directors granted to 13 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 79,500 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into.
Is It Worth Investing in Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) Right Now?
The 36-month beta value for BCYC is at 1.51. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 5 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for BCYC is 61.43M, and currently, shorts hold a 5.10% of that float. The average trading volume for BCYC on May 07, 2025 was 340.37K shares.
BCYC’s Market Performance
The stock of Bicycle Therapeutics Plc ADR (BCYC) has seen a -9.87% decrease in the past week, with a 7.40% rise in the past month, and a -42.59% fall in the past quarter. The volatility ratio for the week is 9.42%, and the volatility levels for the past 30 days are at 9.41% for BCYC. The simple moving average for the past 20 days is -6.43% for BCYC’s stock, with a -57.37% simple moving average for the past 200 days.
Analysts’ Opinion of BCYC
Many brokerage firms have already submitted their reports for BCYC stocks, with Stephens repeating the rating for BCYC by listing it as a “Equal-Weight.” The predicted price for BCYC in the upcoming period, according to Stephens is $25 based on the research report published on November 08, 2024 of the previous year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see BCYC reach a price target of $35. The rating they have provided for BCYC stocks is “Outperform” according to the report published on September 06th, 2024.
B. Riley Securities gave a rating of “Neutral” to BCYC, setting the target price at $28 in the report published on August 07th of the previous year.
BCYC Trading at -16.34% from the 50-Day Moving Average
After a stumble in the market that brought BCYC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.19% of loss for the given period.
Volatility was left at 9.41%, however, over the last 30 days, the volatility rate increased by 9.42%, as shares surge +9.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.22% lower at present.
During the last 5 trading sessions, BCYC fell by -9.87%, which changed the moving average for the period of 200-days by -67.21% in comparison to the 20-day moving average, which settled at $7.91. In addition, Bicycle Therapeutics Plc ADR saw -47.14% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCYC starting from Young Alethia, who sale 215 shares at the price of $8.02 back on Apr 02 ’25. After this action, Young Alethia now owns 45,390 shares of Bicycle Therapeutics Plc ADR, valued at $1,724 using the latest closing price.
Skynner Michael, the CHIEF TECHNOLOGY OFFICER of Bicycle Therapeutics Plc ADR, sale 1,038 shares at $7.48 during a trade that took place back on Apr 03 ’25, which means that Skynner Michael is holding 121,870 shares at $7,764 based on the most recent closing price.
Stock Fundamentals for BCYC
Current profitability levels for the company are sitting at:
- -9.94 for the present operating margin
- 0.78 for the gross margin
The net margin for Bicycle Therapeutics Plc ADR stands at -7.9. The total capital return value is set at -0.31. Equity return is now at value -37.13, with -28.45 for asset returns.
Based on Bicycle Therapeutics Plc ADR (BCYC), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -21.65. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -281.44.
Currently, EBITDA for the company is -164.89 million with net debt to EBITDA at 3.57. When we switch over and look at the enterprise to sales, we see a ratio of -10.59. The receivables turnover for the company is 0.55for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.86.
Conclusion
In conclusion, Bicycle Therapeutics Plc ADR (BCYC) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
